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University of Science and Technology, Wuhan, China
Myocardial injuries in viral myocarditis (VMC) are caused by viral infection and related 
autoimmune disorders. Recent studies suggest that IL-9 mediated both antimicrobial 
immune and autoimmune responses in addition to allergic diseases. However, the role 
of IL-9 in viral infection and VMC remains controversial and uncertain. In this study, we 
infected Balb/c mice with Coxsackievirus B3 (CVB3), and found that IL-9 was enriched 
in the blood and hearts of VMC mice on days 5 and 7 after virus infection. Most of IL-9 
was secreted by CD8+ T cells on day 5 and CD4+ T cells on day 7 in the myocardium. 
Further, IL-9 knockout exacerbated cardiac damage following CVB3 infection, along 
with a sharp increase in viral replication and IL-17a expression, as well as a decrease in 
TGF-β. In contrast, the repletion of IL-9 in Balb/c mice with CVB infection induced the 
opposite effect. Studies in vitro further revealed that IL-9 directly inhibited viral replication 
in cardiomyocytes by reducing coxsackie and adenovirus receptor expression, which 
might be associated with upregulation of TGF-β autocrine effect in these cells. However, 
IL-9 had no direct effect on apoptosis in cardiomyocytes. Our data indicated that IL-9 
played a protective role in disease progression by inhibiting CVB3 replication in the early 
stages of VMC.
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inTrODUcTiOn
Viral myocarditis (VMC) is a triphasic disease including an initial viral infection, followed by auto-
immune response and finally myocardial remodeling (1). Coxsackievirus B3 (CVB3) is the common 
pathogen causing this inflammatory disease (2). Although excessive activation of immune response 
triggered by virus infection is the main factor contributing to myocardial injuries, the virus itself is 
critical to the progression of VMC via direct attack on cardiomyocytes (3).
IL-9, a cytokine produced primarily by CD4+ Th9 cells, is generally reported to mediate 
allergic and autoimmune diseases (4). Recent studies suggest that IL-9 plays an important role in 
infectious diseases including Trichuris muris expulsion and respiratory syncytial virus clearance 
(5, 6). For the influence of IL-9 on VMC and CVB3 infection, only Qing et al. newly observed that 
IL-9-secreting Th9 cells were unchanged in CVB3-induced VMC mice (7). Nevertheless, the effect 
of IL-9 on VMC progression and CVB3 replication remain unknown. Therefore, in this study, we 
investigated the expression of IL-9, viral replication, and related inflammatory factors in VMC using 
IL-9 knockout (IL-9KO/IL-9 −/−) and rIL-9 injected Balb/c mice. Concurrently, the direct effects of 
FigUre 1 | il-9 expressions were increased in myocardium of VMc mice.
(Continued)
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IL-9 on myocardial cells infected with CVB3 were also studied to 
elucidate the mechanism involved.
MaTerials anD MeThODs
Mice
IL-9−/− mice in a Balb/c background were generated as previously 
described (8) and were provided by the Laboratory of Molecular 
Biology, Medical Research Council, Cambridge, UK. Wild-
type male Balb/c mice were purchased from the Experimental 
Animal Center of Hubei province (Wuhan, China). All the 
animals were housed under standard pathogen-free conditions 
at the Experimental Animal Center (Tongji Medical College 
of Huazhong University of Science and Technology, Wuhan, 
China). The animal experiments were carried out according to 
the guidelines for the Care and Utilization of Laboratory Animals 
FigUre 1 |  continued  
(a) The results of immunohistochemistry (magnification 400×) in the heart tissue showed that IL-9 distributed in the lesions with inflammation on days 5 and 7.  
(B) CD45+ cells were gated. And the isotype control of IL-9 was showed. (c) The representative pictures for IL-9-secreting leukocyte (CD45+IL-9+) levels in different 
groups. (D) The results of statistical analysis for IL-9-secreting leukocyte levels by flow cytometry in different groups. (e) The CD45+IL-9+ cells were gated and 
further analyzed for CD11b, Gr-1, CD49b, CD4, and CD8 expressions to detect the cellular source of IL-9. **P < 0.01 vs. control group; ##P < 0.01 vs. IL-9KO 
group. Values are means ± SEM. Ten mice were euthanized in each group separately on days 5 and 7.
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(Huazhong University of Science and Technology, China). And 
this study was approved by the Institutional Animal Care and 
Use Committee of Tongji Medical College, Huazhong University 
of Science and Technology according to the regulations for the 
administration of affairs concerning experimental animals in 
Hubei province of China and the constitution of the experimental 
animal ethics committee in Huazhong University of Science and 
Technology.
Virus and cVB3 infection
The CVB3 (3  m strain, CCTCC GDV115) titer determined by 
plaque-forming unit (PFU) assay in HeLa cells was 1  ×  107. 
IL-9−/− and WT BALB/c mice aged 4 weeks were infected by an 
intraperitoneal (i.p.) injection of 0.2 mL of RPMI-1640 (Gibco) 
containing approximately 105 PFU of CVB3 to establish the VMC 
models. The virus experiments were performed according to the 
general requirements for laboratory biosafety (GB 19489–2008) 
in China.
interventions and groups
IL-9KO and WT BALB/c mice were divided into four groups ran-
domly: (1) control group (n = 20) containing WT BALB/c mice 
treated with saline (300 μL per mouse); (2) WT group (n = 20) 
comprising WT BALB/c mice treated with 200 μL CVB3 and 
100 μL saline; (3) IL-9KO group (n = 20) including IL-9−/−Balb/c 
mice treated with 200 μL CVB3 and 100 μL saline; and (4) rIL-9 
group (n = 20) consisting of mice treated with 200 μL CVB3 and 
rIL-9 (1 μg diluted in 100 μL saline per mouse, PeproTech). The 
intraperitoneal injections of CVB3 and saline were developed on 
day 0. The rIL-9 was administered intraperitoneally on days 0 
and 3. All the animals in each group were euthanized on days 5 
and 7. The blood and hearts were removed aseptically for further 
measurements.
Flow cytometry
Hearts of mice were minced into 1 mm3 sections and digested 
with 0.1% collagenase B (Roche Diagnostics GmbH) for 6 min 
four times in a 37°C water bath (9). Cell suspensions were 
obtained by filtering through a cell strainer (40  μm size, BD 
Falcon) and layered over Ficoll–Hypaque density gradient 
solution to separate mononuclear cells for flow cytometry. 
Intracardiac IL-9-producing leukocytes were measured by labe-
ling the harvested cells with the following surface markers: PE 
anti-mouse CD45, FITC anti-mouse CD4, FITC anti-mouse 
CD49b, PE-cy7 anti-mouse CD11b, PE-cy7 anti-mouse CD8, or 
PE anti-mouse Gr-1 antibodies (eBioscience). After washing with 
PBS, these cells were stimulated with 1 μg/mL ionomycin, 20 ng/
mL phorbol myristate acetate (PMA), and 2 μmol/L monensin 
(eBioscience) for 4 h under 5% CO2 at 37°C in 24-hole culture 
plates (Costar). After washing, fixing, and permeabilizing accord-
ing to the manufacturer’s instructions, the cells were stained with 
APC anti-mouse IL-9 antibody or isotype control antibody. The 
stained cells were measured and analyzed by FACScalibur flow 
cytometry (BD Biosciences).
FigUre 2 | il-9 attenuated the severity of VMc mice. (a) The representative pictures of histopathology (magnification 200×) in heart tissue. (B) The ratios of 
HM/BW in different groups. (c) The pathological scores in different groups. (D) The levels of serum cTnI in different groups. *P < 0.05 vs. control group; **P < 0.01 
vs. control group; #P < 0.05 vs. WT group; ##P < 0.01 vs. WT group. Values are means ± SEM. Ten mice were euthanized in each group separately on days 5 and 
7. HM/BW, the ratios of heart weight to body weight; cTNT, cardiac troponin I.
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histopathology and 
immunohistochemistry
The heart was fixed in 4% paraformaldehyde for 24 h, trimmed, 
and embedded routinely in paraffin. Longitudinal, 5-mm-thick 
sections of heart were obtained for staining with hematoxylin and 
eosin. The severity of impairment was assessed by the percentage 
of cardiac sections showing inflammation compared with the 
overall size of the heart sections, under a microscope eye piece 
grid (magnification 200×) according to the following scoring sys-
tem: grade 0, none; grade 1, 25% cardiac inflammation; grade 2, 
25–50%; grade 3, 50–75%; and grade 4, more than 75% (10). Two 
independent researchers scored the results in a blinded manner.
To further evaluate the cardiac expression of IL-9, the sections 
were heated in a microwave using 0.01% citrate buffer (pH = 9.0) 
and treated with 3% H2O2 for 10 min. After washing with PBS 
buffer three times and blocking with 3% bovine serum albumin 
(BSA) for 30 min, the sections were incubated with hamster anti-
mouse IL-9 IgG (eBioscience) at 4°C overnight and washed with 
PBS buffer three times. After incubation with HRP-conjugated 
anti-hamster antibody for 45  min and washing adequately, 
diaminobenzidine solution was added, and the sections were 
counterstained by hematoxylin.
elisa
Serum levels of IL-9, IL-17a, TGF-β, IL-10, TNF-α, IFN-γ, IFN-α, 
and IFN-β were determined using sensitive mouse IL-9 
(Biolegengd), TNFα/IFN-γ/TGF-β/IL-10/IL-17a (Neobioscience), 
IFN-α (eBioscience), and IFN-β (Pbl Assay Science) kits, accord-
ing to the manufacturers’ instructions. No cross-reactivity was 
detected. Blood concentrations of serum cardiac troponin (cTn) 
T were measured using a quantitative rapid assay kit (Roche 
Diagnostics GmbH Elecsys, Shanghai, China) as previously 
described (11). All the samples were measured in triplicate.
Plaque-Forming assay
A portion of the heart was weighed and homogenized in PBS. 
After three freeze-thaw cycles and centrifugation at 2000 rpm for 
10 min, the supernatant was obtained and sequentially diluted 1:10 
in RPMI 1640 medium. The HeLa cell monolayers were cultured 
in six-well plates with the supernatant for 1 h at 37°C, 5% CO2. 
They were washed in PBS and covered with 2 mL 0.4% agar, RPMI 
1640, and 10% FBS (Gibco). After 72 h of incubation, the number 
of plaques was counted. The viral titers were analyzed by standard 
plaque formation assay and expressed per organ weight (gram).
cardiomyocyte culture
Neonatal cardiomyocytes were isolated as previously described 
(12). The ventricles obtained from 1–3 days BALB/c mice were 
removed rapidly into cold Hanks’ balanced salt solution (HBSS). 
After washing and mincing, tissues were digested in 0.05% 
trypsin (GIBCO) for 30 min at 4°C with rotation. The tissues were 
transferred into DMEM (GIBCO) containing 20% FBS (Fetal 
FigUre 3 | il-9 inhibited cardiac viral replication in VMc mice. (a) The levels of cardiac CVB3 titers were showed on days 5 and 7. Data represent mean 
values of CVB3 PFU per gram of the hearts. (B) The mRNA levels of cardiac CAR expression. (c) The protein levels of cardiac CAR expression. *P < 0.05 vs. 
control group; **P < 0.01 vs. control group; #P < 0.05 vs. WT group; ##P < 0.01 vs. WT group. Values are means ± SEM. Ten mice were euthanized in each group 
separately on days 5 and 7.
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cVB3-infecting cardiomyocytes
The isolated neonatal cardiomyocytes were divided into three 
groups: (1) control group, including neonatal cardiomyocytes 
treated with 50 μL PBS; (2) CVB3 group, comprising neonatal 
cardiomyocytes incubated with CVB3 at 5 × 105 PFU in 50 μL 
PBS; (3) IL-9 group, containing neonatal cardiomyocytes incu-
bated with CVB3 at 5 × 105 PFU in 25 μL PBS and 500 ng/mL 
IL-9 diluted in 25 μL PBS; and (4) IL-9 + TGF-β monoclonal 
antibody (mAb) group, administrating 10 μg/mL TGF-β mAb 
(eBioscience, 1  mg/mL) in the IL-9 group. After 48  h, the 
bovine serum, Gibco) to terminate the digestion. After washing 
with HBSS, the tissues were incubated with Liberase TH (0.1 U/
mL, Roche, Germany) at 37°C for 5  min, and the dissociated 
cells were collected into 20% FBS DMEM. This procedure was 
not repeated until most of the cells were released. The isolated 
cells were incubated with 5% CO2 at 37°C for 1 h. The unattached 
cardiomyocytes were seeded into fibronectin-coated 12-well 
tissue culture plates (Costar) and subsequent experiments were 
performed when the cardiomyocytes formed a confluent mon-
olayer and beat in synchrony at 72 h.
FigUre 4 | il-9 regulated serum il-17a and TgF-β expressions in VMc mice. The levels of serum IL-9, IL-17a, IL-10, TGF-β, TNF-α, IFN-γ, IFN-α, and IFN-β 
in Control, WT, IL-9KO, and rIL-9 groups. *P < 0.05 vs. control group; **P < 0.01 vs. control group; #P < 0.05 vs. WT group; ##P < 0.01 vs. WT group. Values are 
means ± SEM. Ten mice were euthanized in each group separately on days 5 and 7.
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plaque-forming assay was developed as above. The protein was 
extracted for Western Blot test. The supernatant was tested for 
TGF-β, TNF-α, IFN-α, and IFN-β, using ELISA, as mentioned 
above.
apoptosis assay
The cardiomyocytes proliferated over the coverslips in 12-well 
culture plates and were incubated with CVB3 at 5 ×  105  PFU 
or CVB3 + 500 ng/mL IL-9, as described above. After 12 h, the 
RNA was extracted and subjected to real-time PCR for Bax/
Bcl-2 analysis. The TUNEL assay was performed using an in situ 
cell death detection kit (Roche) according to the manufacturer’s 
protocol. The TUNEL-stained slides were washed with PBS 
and counterstained with α-SMA (Boster, Wuhan, China) and 
4′,6-diamidino-2-phenylindole (DAPI; Beyotime, Shanghai, 
China). A laser confocal microscope (Olympus, Tokyo, Japan) 
was used to acquire the images. Nuclei, which were labeled with 
both TUNEL and DAPI, were considered TUNEL-positive.
Western Blot
Total proteins of the heart tissue or cardiomyocyte were extracted 
with the total protein extraction kit (Pierce/Thermo Scientific, 
FigUre 5 | il-9 directly suppressed cVB3 replication in 
cardiomyocyte in vitro. (a) Representative pictures of plaque assay of 
CVB3 in different groups. (B) The results of statistical analysis for CVB3 titers 
in Control, CVB3, and IL-9 groups. (c) The changes of IL-9R and CAR on 
myocardial cells in different groups. **P < 0.01 vs. control group; #P < 0.05 
vs. CVB3 group; ##P < 0.01 vs. CVB3 group. Values are means ± SEM. Each 
experiment was independently performed three times.
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USA). The BCA protein assay kit (Pierce) was used to determine 
protein concentrations. Samples containing 30 μg proteins were 
separated on a 10% SDS-PAGE and electrotransferred onto 
nitrocellulose membranes. The membrane was blocked for 2 h 
in TBST containing 5% skim milk and incubated with primary 
antibodies against IL-9 receptor (IL-9R, 1:500 dilution, Abcam), 
coxsackie and adenovirus receptor (CAR, 1:500 dilution, Santa 
Cruz), phosphorylated Erk1/2 (1:500 dilution, cell signaling 
technology), total Erk1/2 rabbit polyclonal antibody (1:1000 
dilution, cell signaling technology), and beta-actin (1:1000 dilu-
tion, cell signaling technology) at 4°C over night. After washing, 
the membranes were incubated with HRP-conjugated secondary 
antibodies (1:3000) at 37°C for 2 h. The target bands were finally 
developed with super ECL reagent (ThermoScientific, USA), 
captured by Image Lab, and semi-quantitatively analyzed with 
densitometric methods.
real-Time Pcr
Total RNA of heart tissue or cardiomyocyte was extracted with 
TRIzol reagent (Takara Biotechnology) following the manufac-
turer’s protocol and the PrimeScript RT reagent kit was used to 
reverse transcribe the RNA into DNA (Takara Biotechnology). 
The primers for CAR, Bax, Bcl-2, and GAPDH are listed: CAR 
(Sense: GCACCCGCTAAGGTAGCTG, Antis: ATAGACCCGTC 
CTTGCTCTGT), Bax (Sense: TGCAGAGGATGATTGCTGAC, 
Antis: GATCAGCTCGGGCACTTTAG), Bcl-2 (Sense: 
GTACCTGAACCGGCATCTG, Antis: GCTGAGCAGGGTC 
TTCAGAG), and GAPDH (Sense: CACGGCAAATTCAACGGC, 
Antis: TGATGA CCCTTTTGGCTCCA). After an initial dena-
turation step at 94°C for 3  min, a three-step cycle procedure 
(denaturation: 94°C, 30 s; annealing: 58°C, 30 s; and extension: 
72°C, 30 s) was carried out for 40 cycles. The mRNA levels of tar-
get genes were quantified using SYBR Green Master Mix (Takara 
Biotechnology) with CFX connect real-time system (Biorad, 
USA). The relative level of gene expression was normalized to the 
level of GAPDH transcripts.
statistical analysis
Data are presented as means  ±  SEM. Statistical analysis was 
performed by one-way ANOVA using SPSS 11.0, and P < 0.05 
was considered statistically significant.
resUlTs
increased il-9 expression in Myocardium 
of VMc Mice
IL-9 protein expression in myocardium was enhanced on days 
5 and 7 in WT and rIL-9 groups, compared with that of the 
control group (Figure  1A). Further, IL-9-secreting leukocyte 
(CD45+IL-9+) levels were significantly increased in WT and rIL-9 
groups on days 5 and 7 compared with those in the control and 
IL-9 KO group (Figures  1B–D, all P <  0.01). These cells were 
higher in WT and rIL-9 groups on day 5 than on day 7. In addition, 
IL-9 protein and IL-9-secreting leukocytes in myocardium were 
almost not expressed in the IL-9 KO mice (Figures 1A–D). Thus, 
IL-9 expression was increased in myocardium of VMC mice.
To identify the leukocytes contributing to cardiac IL-9 secre-
tion in VMC, we stained the cells with various surface markers. 
Most of the IL-9-secreting leukocytes were CD8-positive on day 
5, and the majority of these cells were CD4-positive on day 7 
(Figure 1E).
il-9 attenuated the severity of VMc
The HW/BW (the ratios of heart weight to body weight), the 
pathological scores of heart sections and cTNT levels in WT, 
IL-9KO, and rIL-9 groups were elevated significantly compared 
with those in the control group (all P <  0.05). However, these 
three indices for evaluation of VMC severity were enhanced 
in the IL-9KO group compared with those in the WT group 
(all P < 0.05). The severity of VMC was suppressed in rIL-9 group 
compared with WT group (all P < 0.05; Figure 2). From this, we 
found that IL-9 could attenuate the severity of VMC.
il-9 inhibited cardiac Viral replication  
in VMc
On days 5 and 7, the levels of cardiac CVB3 titers and CAR 
expressions in WT, IL-9KO, and rIL-9 groups were increased 
compared with those in the control group (all P <  0.05). The 
viral titers and CAR expressions in IL-9KO group were higher 
than those in WT group (P < 0.05). However, they were lower in 
rIL-9 group (P < 0.05). The control group was tested negative for 
cardiac CVB3 (Figure 3). These data proved that IL-9 inhibited 
cardiac viral replication and CAR expression in VMC mice.
il-9 regulated serum il-17a and  
TgF-β expression in VMc Mice
Except for IL-10, the levels of serum IL-9, IL-17a, TGF-β, TNF-
α, IFN-γ, IFN-α, and IFN-β in WT, IL-9KO, and rIL-9 groups 
FigUre 6 | il-9 facilitated TgF-β autocrine effect from cardiomyocyte in vitro. (a) The levels of autocrine TGF-β, TNF-α, IFN-α, and IFN-β from myocardial 
cells. (B) The changes of signal molecule phosphorylated ERK1/2 and RhoA were showed in different groups. (c) The levels of CVB3 titer, CAR mRNA, and CAR 
protein of myocardial cells treated with IL-9 or IL-9 + TGF-β mAb. *P < 0.05 vs. control group; **P < 0.01 vs. control group; #P < 0.05 vs. CVB3 group; ##P < 0.01 
vs. CVB3 group; $P < 0.05 vs. IL-9 group. Values are means ± SEM. Each experiment was independently performed three times.
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were higher than in control mice on days 5 and 7 (all P < 0.05). 
However, the decreased IL-9 level in the IL-9KO group was 
accompanied by enhanced IL-17a levels and attenuated TGF-
β levels compared with those in WT group (all P  <  0.01). 
The opposite changes in IL-9, IL-17a, and TGF-β levels were 
detected in rIL-9 groups compared with those in WT group 
(all P <  0.01, Figure  4). This indicated that IL-9 downregu-
lated IL-17a expression and upregulated TGF-β expression in 
VMC mice.
il-9 Directly suppressed cVB3 replication 
in cardiomyocytes In Vitro
The direct effects of IL-9 on myocardial cells were investigated 
in vitro. The neonatal cardiomyocytes were isolated, infected with 
CVB3, and incubated with IL-9. The CVB3 titers in the CVB3 
and IL-9 groups were higher than in the control group (P < 0.01). 
However, the viral titers in IL-9 group were lower than in the 
CVB3 group (P < 0.05). CVB3 was not detected in the control 
group (Figures 5A,B).
To clarify the role of IL-9 in CVB3 replication in the cardio-
myocytes, we determined the changes in IL-9R and CAR levels 
of myocardial cells. We first found that cardiomyocytes express 
IL-9R. Subsequently, we found that the CAR protein levels in 
myocardial cells were increased in the CVB3 and IL-9 groups 
compared with those in the control group (P  <  0.01). They 
were lower in the IL-9 group than in the CVB3 group (P < 0.01, 
Figure 5C). Thus, IL-9 could directly suppress CVB3 replication 
and CAR expression in cardiomyocytes.
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il-9 Facilitated TgF-β autocrine effect  
in cardiomyocytes In Vitro
The autocrine effect of TGF-β, TNF-α, IFN-α, and IFN-β from 
myocardial cells was detected after neonatal cardiomyocytes were 
infected with CVB3 and incubated with IL-9. The levels of the 
four cytokines were higher in the CVB3 and IL-9 groups than in 
the control group (all P < 0.05). However, only TGF-β levels were 
higher in the IL-9 group than in the CVB3 group (P < 0.05). No 
differences in TNF-α, IFN-α, and IFN-β were found between the 
CVB3 and IL-9 groups (Figure 6A).
The signal molecules associated with TGF-β production in 
myocardial cells were investigated. The phosphorylated ERK1/2 
levels were increased after CVB3 infection (P < 0.01) and were 
attenuated after IL-9 treatment (P < 0.05; Figure 6B). The other 
signal molecule RhoA was not altered following CVB3 and IL-9 
interventions (Figure 6B).
Then, the TGF-β mAb in combination with IL-9 were added 
to further clarify the mechanisms of IL-9 on CVB3 replication 
and CAR expression. The data showed that the CVB3 titers and 
CAR expression in IL-9 + TGF-β mAb group were higher than 
in the IL-9 group (P < 0.05; Figure 6C). It further indicated that 
IL-9 could suppress CVB3 replication and CAR expression by 
facilitating TGF-β autocrine effect in cardiomyocytes.
il-9 Did not Directly influence 
cardiomyocyte apoptosis In Vitro
To test the effects of IL-9 on cardiomyocyte apoptosis after CVB3 
infection in vitro, we carried out TUNEL in myocardial cells. As 
shown in Figures  7A,B, CVB3 infection remarkably increased 
the number of TUNEL-positive cardiomyocytes compared with 
the control groups (P < 0.05). However, no significant differences 
were found in the number of TUNEL-positive cells between IL-9 
and CVB3 groups.
We also examined the concurrent expression of Bcl-2 fam-
ily using real-time PCR. The Bax/Bcl-2 ratio was significantly 
increased in cardiomyocytes exposed to CVB3 (P  <  0.01). 
However, no changes in Bax/Bcl-2 ratio were found between 
IL-9 and CVB3 groups (Figure 7C). Thus, IL-9 did not directly 
influence cardiomyocyte apoptosis.
DiscUssiOn
In this study, we first found that the serum IL-9 levels were 
elevated in VMC mice. Further, the number of IL-9-secreting 
leukocytes and IL-9 protein expression in myocardial tissue were 
increased on days 5 and 7 in VMC. Furthermore, most of the 
IL-9-secreting leukocytes were CD8+ on day 5 and CD4+ on day 7 
in the myocardium, suggesting that CD8+ and CD4+ T cells might 
be the major source of IL-9 in VMC.
In the early stage of VMC, the direct attack by the virus was the 
primary cause of myocardial injury (13). We found that depletion 
of IL-9 facilitated virus replication along with enhanced myocar-
dial injury. IL-9 supplementation depressed the viral replication 
and attenuated the myocardial injury. It suggested that IL-9 ame-
liorated the progression of VMC by inhibiting CVB3 replication. 
Cytokines play an important role in VMC by regulating antiviral 
immunity. IFN-γ, IFN-α, and IFN-β are the primary cytokines 
mediating viral death and clearance via macrophage activation 
(13, 14). TGF-β reduced viral replication and CVB3-mediated 
autoimmunity in the early stages of VMC (15). TNF-α is the main 
proinflammatory cytokine that exacerbated myocarditis through 
excessive autoimmunity (16). IL-17a facilitated viral replication 
in VMC by inhibiting IFN-γ production (17–19). The finding 
demonstrated that IL-9 depletion boosted IL-17a expression 
and inhibited TGF-β expression, while IL-9 supplementation 
suppressed IL-17a expression and accelerated TGF-β expression. 
IL-9 did not regulate the expression of IFN-γ, IFN-α, IFN-β, and 
TNF-α. These data indicated that IL-9 inhibited CVB3 replication 
by indirectly regulating IL-17a and TGF-β expression.
To further explore the direct mechanisms of IL-9 in VMC, 
we isolated neonatal cardiomyocytes and infected the cells with 
CVB3 followed by incubation with IL-9. The data suggested that 
IL-9R expression on cardiomyocytes and IL-9 directly inhibited 
CVB3 replication by binding to IL-9R. Further, administration 
of IL-9 reduced the levels of CAR, which is the primary receptor 
for CVB3 infection on cardiomyocytes. Therefore, IL-9 directly 
inhibited CVB3 infection by downregulating CAR expression.
The expression of CAR on cardiomyocytes was locally modu-
lated by autocrine regulation of cytokines in myocardial cells. 
IFN-α, IFN-β, TNF-α, and TGF-β represent the main autocrine 
cytokines in cardiomyocytes (20–24). We detected changes 
in these cytokines and found that IL-9 only promoted TGF-β 
expression. The increased TGF-β level reduced CAR expression 
on cardiomyocytes, which suppressed CVB3 replication (16) and 
further suggested that IL-9 directly inhibited viral replication 
FigUre 7 | il-9 did not directly influence cardiomyocyte apoptosis 
in vitro. (a) The representative pictures for TUNEL-positive myocardial cells. 
α-SMA: red. DAPI: blue. TUNEL: green. (B) The statistical analysis for the 
number of TUNEL-positive cardiomyocytes. (c) The ratio of Bax/Bcl-2 mRNA 
was analyzed. *P < 0.05 vs. control group; **P < 0.01 vs. control group. 
Values are means ± SEM. Each experiment was independently performed 
three times.
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